Pharmacogenomics: Challenges and Future

Over the last few decades, the implementation of pharmacogenomics (PGx) in clinical practice has improved tailored drug prescriptions. PGx investigates how individual genetic makeup influences variability in drug response in terms of pharmacokinetics (PK) and pharmacodynamics (PD), adverse drug reactions, and clinical outcomes. Although the FDA provides recommendations for drug absorption, distribution, metabolism, and elimination (ADME)-related genes for over 200 drugs in several therapeutic areas, especially for cancer, there are several barriers to the full implementation of PGx. This Special Issue contains six research articles and five reviews, one of which is a systematic review. The manuscripts cover several topics of interest in the PGx field, including bioinformatic approaches for data analysis and biomarker discovery and validation.